NCT06309992已完成3 期
Multicentre, Randomised, Double-blind, Placebo-controlled, 48-week, Phase III Trial to Evaluate the Efficacy and Safety of Survodutide Administered Subcutaneously in Participants With Overweight or Obesity and Presumed or Confirmed Nonalcoholic Steatohepatitis (NASH)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 218
- 试验地点
- 69
- 主要终点
- Relative change (%) in body weight [kg] from baseline to Week 48
研究概览
简要总结
This study is open to adults who are at least 18 years old and have
- presumed or confirmed NASH together with overweight or obesity and
- a body mass index (BMI) of 30 kg/m² or more, or
- a BMI of 27 kg/m² and at least one weight-related health problem.
People with a history of other chronic liver diseases cannot take part in this study.
The purpose of this study is to find out whether a medicine called survodutide helps people living with obesity or overweight and a confirmed or presumed liver disease called nonalcoholic steatohepatitis (NASH) to have less liver fat and to lose weight. Participants are put into 2 groups randomly, which means by chance. 1 group gets different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week for about 1 year. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.
Participants are in the study for about 1 year and 3 months. During this time, it is planned that participants visit the study site up to 14 times and receive 3 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At 3 of the visits, the participants' liver is measured using different imaging methods. The results are compared between the groups to see whether the treatment works.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is >18 years
- •BMI ≥30 kg/m², OR BMI ≥27 kg/m² and at least one of the following weight-related comorbidities at screening:
- •Hypertension (defined as repeated, i.e. at least 3 measurements in resting condition, Systolic Blood Pressure (SBP) values of ≥140 mmHg and/or Diastolic Blood Pressure (DBP) values of ≥90 mmHg in the absence of anti-hypertensive treatment, or intake of at least 1 antihypertensive drug to maintain a normotensive blood pressure)
- •Dyslipidaemia (defined as at least 1 lipid-lowering treatment required to maintain normal blood lipid levels, or lowdensity lipoprotein (LDL) cholesterol ≥160 mg/dL (≥4.1 mmol/L) or triglycerides ≥150 mg/dL (≥1.7 mmol/L), or high-density lipoprotein (HDL) cholesterol <40 mg/dL (<1.0 mmol/L) for men or HDL cholesterol <50 mg/dL (<1.3 mmol/L) for women
- •Obstructive sleep apnoea
- •Cardiovascular disease (e.g. heart failure with New York Heart Association (NYHA) functional class II-III, history of ischaemic or haemorrhagic stroke or cerebrovascular revascularisation procedure [e.g. carotid endarterectomy and/or stent], MI, coronary artery disease, or peripheral vascular disease)
- •Type 2 diabetes mellitus (T2DM) (diagnosed at least 180 days prior to screening, with glycated haemoglobin [HbA1c] ≥6.5% (48 mmol/mol) and <10% (86 mmol/mol) as measured by the central laboratory at screening)
- •History of at least one self-reported unsuccessful dietary effort to lose body weight Further inclusion criteria apply.
排除标准
- •Current or history of significant alcohol consumption (defined as intake of >210 g/week in men and >140 g/week in women on average over a consecutive period of more than 3 months) or inability to reliably quantify alcohol consumption based on the investigator's judgement within the last 5 years.
- •Intake of medications associated with liver injury, hepatic steatosis or steatohepatitis.
- •History of other chronic liver diseases (e.g. viral hepatitis, autoimmune liver disease, primary biliary cholangitis , primary sclerosing cholangitis, Wilson's disease, hemochromatosis, Alpha-1 Antitrypsin (A1At) deficiency, history of liver transplantation). Hepatitis B and C testing will be done at Visit
- •Participants with positive hepatitis B surface antigen (HBsAg) should be excluded. Participants treated for hepatitis C must have a negative ribonucleic acid (RNA) test at screening and also be Hepatitis C virus (HCV) RNA negative for at least 3 years prior to screening in order to be eligible for the trial. Trial participants with positive HCV antibody and no history of HCV treatment require a negative HCV RNA test at screening to be eligible for the trial.
- •Cirrhosis based on clinical assessment, abdominal imaging, liver histology or non-invasive tests assessed at screening (enhanced liver fibrosis (ELF) ≥11.3 or Fibrosis (FIB)-4 ≥3.48 or FibroScan® VCTE™ ≥20 kPa or MRE ≥4.68 kPa) or a history of cirrhosis.
- •Current decompensated liver disease or previous hepatic decompensation (ascites, spontaneous bacterial peritonitis, portal hypertension bleeding, hepatic encephalopathy, hepatorenal syndrome).
- •Evidence of portal hypertension (e.g. splenomegaly, oesophageal varices, or other portosystemic collateral pathways).
- •Further exclusion criteria apply.
研究组 & 干预措施
Placebo arm
Placebo Comparator
干预措施: Placebo (Combination Product)
Treatment arm
Experimental
干预措施: Survodutide (Combination Product)
结局指标
主要结局
Relative change (%) in body weight [kg] from baseline to Week 48
时间窗: at baseline, at week 48
Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%]
时间窗: at baseline, at week 48
次要结局
- Relative change in liver volume [mL] from baseline to Week 48 measured using MRI(at baseline, at week 48)
- Absolute change in liver volume [mL] from baseline to Week 48 measured using MRI(at baseline, at week 48)
- Absolute change from baseline to Week 48 in liver stiffness [kPa] assessed by magnetic resonance elastography (MRE)(at baseline, at week 48)
- Relative change from baseline to Week 48 in liver stiffness [kPa] assessed by magnetic resonance elastography (MRE)(at baseline, at week 48)
- Absolute change from baseline to Week 48 in liver fat content assessed by MRI-PDFF [%](at baseline, at week 48)
- Relative change (%) from baseline to Week 48 in liver fat content assessed by MRI-PDFF [%](at baseline, at week 48)
- Reduction from baseline to Week 48 in Iron corrected T1 (cT1) [ms] levels of ≥80 ms (yes/no)(at baseline, at week 48)
- Absolute change from baseline to Week 48 in alanine amino transferase (ALT) [U/L] levels(at baseline, at week 48)
- Relative change from baseline to Week 48 in alanine amino transferase (ALT) [U/L] levels(at baseline, at week 48)
- Absolute change from baseline to Week 48 in waist circumference [cm](at baseline, at week 48)
- Relative change from baseline to Week 48 in waist circumference [cm](at baseline, at week 48)
- Absolute change from baseline to Week 48 in Homeostasis Model Assessment -Insulin Resistance (HOMA-IR) (Fasting Plasma Insulin (FPI) [mlU/L] · Fasting Plasma Glucose (FPG) [mmol/L]/22.5)(at baseline, at week 48)
- Relative change from baseline to Week 48 in HOMA-IR (FPI [mlU/L] · FPG [mmol/L]/22.5)(at baseline, at week 48)
研究者
研究点 (69)
Loading locations...
相似试验
已完成
3 期
Memory Impairment Study (Mild Cognitive Impairment Study)Alzheimer DiseaseNCT00000173National Institute on Aging (NIA)
已完成
1 期
Trial of swine influenza vaccine in healthy adultsInfection - Other infectious diseasesSwine influenzaACTRN12609000674235Vaxine Pty Ltd300
终止
不适用
Managing Chronic Obstructive Pulmonary Disease(COPD)Together: Participant-CENTREd Continuum of Care (PCCC). A comparison of telephone health-mentoring, home-based walking and rehabilitation with rehabilitation only.Chronic Obstructive Pulmonary Disease (COPD)Respiratory - Chronic obstructive pulmonary diseasePhysical Medicine / Rehabilitation - PhysiotherapyACTRN12611001034921Menzies Research Institute Tasmania, University of Tasmania74
已完成
不适用
Prospective, multicentre, randomised, double-blinded and placebo-controlled clinical trial on the efficacy and safety of clonidine as a co-medication in analgesia and sedation of long-term-ventilated neonates and infantsong-term ventilated infantsNeonatal DiseasesOther respiratory diseases originating in the perinatal periodISRCTN77772144niversity Hospital of Cologne (Germany)210
进行中（未招募）
不适用
A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis - N/ARelapsing-Remitting Multiple SclerosisEsclerosis Múltiple recidivante-remitenteMedDRA version: 8.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2006-003697-10-EEBiogen Idec Ltd.1,232